<DOC>
	<DOCNO>NCT00233974</DOCNO>
	<brief_summary>RATIONALE : Comparing result diagnostic procedure , molecular marker profiling , do chemotherapy , may help doctor predict patient 's response treatment help plan best treatment . PURPOSE : This phase II trial study well molecular marker profile axillary lymph node work predict response patient locally advance metastatic breast cancer undergo chemotherapy follow surgery .</brief_summary>
	<brief_title>Molecular Marker Profiling Axillary Lymph Nodes Predicting Response Patients With Locally Advanced Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether molecular marker pretreatment axillary lymph node metastases predict pathologic response neoadjuvant chemotherapy patient locally advance early metastatic breast cancer . Secondary - Compare molecular marker axillary lymph node metastasis primary breast tumor ( obtain protocol UNC-LCCC-9819 ) patient treat neoadjuvant chemotherapy . - Determine change molecular marker lymph node treatment neoadjuvant chemotherapy patient . - Determine proportion clinical axillary lymph node-negative patient histopathologically node-positive disease identify sentinel lymph node biopsy . - Determine rate breast preservation patient large breast cancer treat neoadjuvant chemotherapy follow fludeoxyglucose F 18 positron emission tomography probe-guided surgical resection . OUTLINE : Patients undergo open surgical biopsy axillary lymph node OR intraoperative lymphatic mapping sentinel lymphadenectomy clinically node-positive clinically node-negative disease , respectively , neoadjuvant chemotherapy . The axillary lymph node tissue examine molecular protein marker immunohistochemistry fluorescence situ hybridization . Patients also undergo fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) neoadjuvant chemotherapy . Beginning 1 hour surgery , patient receive injection FDG undergo conventional segmental mastectomy ( lumpectomy ) without needle localization follow FDG-PET probe-guided surgical resection remain FDG-avid tumor tissue . PROJECTED ACCRUAL : A total 100 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer fine needle aspiration biopsy Locally advance early metastatic disease Clinically radiographically measurable disease Planning receive neoadjuvant chemotherapy locally advance early metastatic disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age Not specify Sex Not specify Menopausal status Not specify Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy malignancy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>